• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Pravalip
    / Unipharm


    Active Ingredient
    Pravastatin Sodium 10, 20, 40 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 X 10 mg

    partial basket chart 13197 16696

    Tablets

    30 X 20 mg

    full basket chart 13198 16697

    Tablets

    30 X 40 mg

    partial basket chart 13199 16698

    Related information


    Dosage

    10-40 mg daily at bedtime.
    Response within 1-2 weeks.
    Maximal effect is within 4 weeks.
    Elderly: Initiate at lower dose and monitor.


    Indications

    As a component of multiple risk intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Should be used in addition to a diet after other nonpharmacological measures alone have been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients without clinically evident coronary heart disease, treatment is indicated to: 1) Reduce the risk of myocardial infarction. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death by non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease, including prior MI, therapy is indicated to: Slow the progression of coronary atherosclerosis; reduce the risk of acute coronary events. Myocardial infarction: In patients with previous myocardial infarction, and normal cholesterol levels, treatment is indicated to: Reduce the risk of recurrent myocardial infarction; reduce the risk of undergoing myocardial revascularization procedures; reduce the risk of stroke or transient ischemic attack (TIA). Hypercholesterolemia and mixed dyslipidemia: Treatment is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb).


    Contra-Indications

    Hypersensitivity. Pregnancy. Lactation. Active liver disease or  constant, unexplained elevation in liver function test results.


    Manufacturer
    Unipharm Ltd.
    CLOSE